Literature DB >> 25269487

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

Gottfried E Konecny1, Chen Wang1, Habib Hamidi1, Boris Winterhoff1, Kimberly R Kalli1, Judy Dering1, Charles Ginther1, Hsiao-Wang Chen1, Sean Dowdy1, William Cliby1, Bobbie Gostout1, Karl C Podratz1, Gary Keeney1, He-Jing Wang1, Lynn C Hartmann1, Dennis J Slamon1, Ellen L Goode1.   

Abstract

Molecular classification of high-grade serous ovarian cancer (HGSOC) using transcriptional profiling has proven to be complex and difficult to validate across studies. We determined gene expression profiles of 174 well-annotated HGSOCs and demonstrate prognostic significance of the prespecified TCGA Network gene signatures. Furthermore, we confirm the presence of four HGSOC transcriptional subtypes using a de novo classification. Survival differed statistically significantly between de novo subtypes (log rank, P = .006) and was the best for the immunoreactive-like subtype, but statistically significantly worse for the proliferative- or mesenchymal-like subtypes (adjusted hazard ratio = 1.89, 95% confidence interval = 1.18 to 3.02, P = .008, and adjusted hazard ratio = 2.45, 95% confidence interval = 1.43 to 4.18, P = .001, respectively). More prognostic information was provided by the de novo than the TCGA classification (Likelihood Ratio tests, P = .003 and P = .04, respectively). All statistical tests were two-sided. These findings were replicated in an external data set of 185 HGSOCs and confirm the presence of four prognostically relevant molecular subtypes that have the potential to guide therapy decisions.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25269487      PMCID: PMC4271115          DOI: 10.1093/jnci/dju249

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

2.  Suppression of IRF4 by IRF1, 3, and 7 in Noxa expression is a necessary event for IFN-γ-mediated tumor elimination.

Authors:  Sujan Piya; Ae Ran Moon; Peter I Song; John Hiscott; Rongtuan Lin; Dai-Wu Seol; Tae-Hyoung Kim
Journal:  Mol Cancer Res       Date:  2011-08-04       Impact factor: 5.852

3.  Diagnosis of multiple cancer types by shrunken centroids of gene expression.

Authors:  Robert Tibshirani; Trevor Hastie; Balasubramanian Narasimhan; Gilbert Chu
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  Beyond chemotherapy: targeted therapies in ovarian cancer.

Authors:  Timothy A Yap; Craig P Carden; Stan B Kaye
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

6.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

Authors:  Roel G W Verhaak; Pablo Tamayo; Ji-Yeon Yang; Diana Hubbard; Hailei Zhang; Chad J Creighton; Sian Fereday; Michael Lawrence; Scott L Carter; Craig H Mermel; Aleksandar D Kostic; Dariush Etemadmoghadam; Gordon Saksena; Kristian Cibulskis; Sekhar Duraisamy; Keren Levanon; Carrie Sougnez; Aviad Tsherniak; Sebastian Gomez; Robert Onofrio; Stacey Gabriel; Lynda Chin; Nianxiang Zhang; Paul T Spellman; Yiqun Zhang; Rehan Akbani; Katherine A Hoadley; Ari Kahn; Martin Köbel; David Huntsman; Robert A Soslow; Anna Defazio; Michael J Birrer; Joe W Gray; John N Weinstein; David D Bowtell; Ronny Drapkin; Jill P Mesirov; Gad Getz; Douglas A Levine; Matthew Meyerson
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

7.  Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples.

Authors:  Craig April; Brandy Klotzle; Thomas Royce; Eliza Wickham-Garcia; Tanya Boyaniwsky; John Izzo; Donald Cox; Wendell Jones; Renee Rubio; Kristina Holton; Ursula Matulonis; John Quackenbush; Jian-Bing Fan
Journal:  PLoS One       Date:  2009-12-03       Impact factor: 3.240

8.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

9.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

View more
  131 in total

1.  Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.

Authors:  Stefan Kommoss; Boris Winterhoff; Ann L Oberg; Gottfried E Konecny; Chen Wang; Shaun M Riska; Jian-Bing Fan; Matthew J Maurer; Craig April; Viji Shridhar; Friedrich Kommoss; Andreas du Bois; Felix Hilpert; Sven Mahner; Klaus Baumann; Willibald Schroeder; Alexander Burges; Ulrich Canzler; Jeremy Chien; Andrew C Embleton; Mahesh Parmar; Richard Kaplan; Timothy Perren; Lynn C Hartmann; Ellen L Goode; Sean C Dowdy; Jacobus Pfisterer
Journal:  Clin Cancer Res       Date:  2017-02-03       Impact factor: 12.531

2.  miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.

Authors:  X Zhu; H Shen; X Yin; L Long; C Xie; Y Liu; L Hui; X Lin; Y Fang; Y Cao; Y Xu; M Li; W Xu; Y Li
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

3.  Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.

Authors:  Alexia T Kedves; Scott Gleim; Xiaoyou Liang; Dennis M Bonal; Frederic Sigoillot; Fred Harbinski; Sneha Sanghavi; Christina Benander; Elizabeth George; Prafulla C Gokhale; Quang-De Nguyen; Paul T Kirschmeier; Robert J Distel; Jeremy Jenkins; Michael S Goldberg; William C Forrester
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

4.  MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.

Authors:  Chia-Hao Tung; Li-Wei Kuo; Meng-Fan Huang; Yi-Ying Wu; Yao-Tsung Tsai; Jia-En Wu; Keng-Fu Hsu; Yuh-Ling Chen; Tse-Ming Hong
Journal:  Oncogene       Date:  2019-09-30       Impact factor: 9.867

5.  Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.

Authors:  Qing Zhang; Chen Wang; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-11-15       Impact factor: 5.482

6.  Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.

Authors:  Chen Wang; Sebastian M Armasu; Kimberly R Kalli; Matthew J Maurer; Ethan P Heinzen; Gary L Keeney; William A Cliby; Ann L Oberg; Scott H Kaufmann; Ellen L Goode
Journal:  Clin Cancer Res       Date:  2017-03-09       Impact factor: 12.531

7.  Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity.

Authors:  Clara Bodelon; J Keith Killian; Joshua N Sampson; William F Anderson; Rayna Matsuno; Louise A Brinton; Jolanta Lissowska; Michael S Anglesio; David D L Bowtell; Jennifer A Doherty; Susan J Ramus; Aline Talhouk; Mark E Sherman; Nicolas Wentzensen
Journal:  Clin Cancer Res       Date:  2019-05-29       Impact factor: 12.531

8.  Extracting a biologically relevant latent space from cancer transcriptomes with variational autoencoders.

Authors:  Gregory P Way; Casey S Greene
Journal:  Pac Symp Biocomput       Date:  2018

9.  Functional network community detection can disaggregate and filter multiple underlying pathways in enrichment analyses.

Authors:  Lia X Harrington; Gregory P Way; Jennifer A Doherty; Casey S Greene
Journal:  Pac Symp Biocomput       Date:  2018

10.  Single-Cell RNA Sequencing of Ovarian Cancer: Promises and Challenges.

Authors:  Shobhana Talukdar; Zenas Chang; Boris Winterhoff; Timothy K Starr
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.